BioCina to expand mRNA vaccines capabilities

Biotechnology company BioCina is expanding the capabilities of its Australian biologics facility (pictured), broadening its capabilities to manufacture mRNA-based vaccines and therapies. The factory, formerly owned by vaccines manufacturer Pfizer, is to employ a range of technologies from associated companies Cytiva and others associated with American medical group of companies Danaher, as well as collaborater…

Details

Snakebite treatment stems severe bleeding

University of Queensland researchers have inspiration from nature to develop unique hydrogels derived from snakes that can save people from blood loss incurred during traumatic injury. Based at the Australian Institute for Bioengineering and Nanotechnology (AIBN), postdoctoral research fellow Dr Amanda Kijas and Professor Alan Rowan looked at compounds in snake venom that activate the…

Details

Defence partnering for success – Riding the AUKUS wave, part 2 By Sarah Pavillard

Yesterday in Part 1 of this two-part analysis, Sarah Pavillard outlined the policy needed to support SMEs into AUKUS supply chains. Today, as we continue our sponsored series reporting BAE Systems Australia’s Partnering for success defence industry supplier event, she argues that industry needs to come to the party too. The AUKUS agreement is a…

Details